These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8265611)

  • 21. Progress towards measles elimination in Singapore.
    Ho HJ; Low C; Ang LW; Cutter JL; Tay J; Chan KP; Ooi PL; Thoon KC; Goh KT
    Vaccine; 2014 Dec; 32(51):6927-6933. PubMed ID: 25444818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological survey of measles immunity in the Czech Republic, 2013.
    Tomášková H; Zelená H; Kloudová A; Tomášek I
    Cent Eur J Public Health; 2018 Mar; 26(1):22-27. PubMed ID: 29684293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identify the susceptibility profile to measles in the general population: Serological survey of measles antibodies in Shaanxi province, China, in 2016.
    Pei L; Yang Y; Zhao X; Zhang S; Yuan L; Liu Y; Yu Y
    Vaccine; 2017 Dec; 35(52):7250-7255. PubMed ID: 29153585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of measles antibodies before and after vaccination in previously unvaccinated children of the Cordillera Province (Santa Cruz Department, Bolivia).
    Guglielmetti P; Bianchi Bandinelli ML; Bartoloni A; Gamboa H; Roselli M; Valensin PE
    J Trop Med Hyg; 1994 Aug; 97(4):231-5. PubMed ID: 8064946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran.
    Karimi A; Arjomandi A; Alborzi A; Rasouli M; Kadivar MR; Obood B; Pourabbas B
    East Mediterr Health J; 2004; 10(4-5):468-73. PubMed ID: 16335636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Declining measles antibodies in the era of elimination: Australia's experience.
    Gidding HF; Quinn HE; Hueston L; Dwyer DE; McIntyre PB
    Vaccine; 2018 Jan; 36(4):507-513. PubMed ID: 29269156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Measles: immunity and vaccination status in Greater Frankfurt on the Main].
    Friedrichs I; Doerr HW; Allwinn R
    Dtsch Med Wochenschr; 2012 Jan; 137(4):121-5. PubMed ID: 22259164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Characteristics of measles epidemics in the Donetsk region population under conditions of regular immunization].
    Slusar' LI; Kolomiĭtseva GN; Erokhina EV; Belomeria TA; Soshenko II; Kovaleva AG
    Lik Sprava; 2002; (2):123-5. PubMed ID: 12073243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.
    Izadi S; Zahraei SM; Mokhtari-Azad T
    Hum Vaccin Immunother; 2018 Jun; 14(6):1412-1416. PubMed ID: 29420120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An increasing, potentially measles-susceptible population over time after vaccination in Korea.
    Kang HJ; Han YW; Kim SJ; Kim YJ; Kim AR; Kim JA; Jung HD; Eom HE; Park O; Kim SS
    Vaccine; 2017 Jul; 35(33):4126-4132. PubMed ID: 28669617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National serologic survey of measles immunity among persons 6 years of age or older, 1988-1994.
    Hutchins SS; Redd SC; Schrag S; Kruszon-Moran D; Wooten K; McQuillan GM; Bellini W; Meyer PA; Hadler S
    MedGenMed; 2001 Jan; ():E5. PubMed ID: 11320344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the Number of Measles-Susceptible Children and Adolescents in the United States Using Data From the National Immunization Survey-Teen (NIS-Teen).
    Bednarczyk RA; Orenstein WA; Omer SB
    Am J Epidemiol; 2016 Jul; 184(2):148-56. PubMed ID: 27338281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
    Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A
    East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation of the Population Susceptibility Against Measles in Slovakia.
    Zibolenová J; Chladná Z; Švihrová V; Baška T; Waczulíková I; Hudečková H
    Cent Eur J Public Health; 2017 Mar; 25(1):46-54. PubMed ID: 28399355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of nationwide measles vaccination campaign among children aged 9 months to 14 years, Zimbabwe, 1998-2001.
    Munyoro MN; Kufa E; Biellik R; Pazvakavambwa IE; Cairns KL
    J Infect Dis; 2003 May; 187 Suppl 1():S91-6. PubMed ID: 12721898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles in developing countries. Part I. Epidemiological parameters and patterns.
    McLean AR; Anderson RM
    Epidemiol Infect; 1988 Feb; 100(1):111-33. PubMed ID: 3338500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal.
    Gonçalves G; Frade J; Nunes C; Mesquita JR; Nascimento MS
    Vaccine; 2015 Sep; 33(39):5057-63. PubMed ID: 26319061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.